46 research outputs found
Modal and Polarization Qubits in Ti:LiNbO Photonic Circuits for a Universal Quantum Logic Gate
Lithium niobate photonic circuits have the salutary property of permitting
the generation, transmission, and processing of photons to be accommodated on a
single chip. Compact photonic circuits such as these, with multiple components
integrated on a single chip, are crucial for efficiently implementing quantum
information processing schemes. We present a set of basic transformations that
are useful for manipulating modal qubits in Ti:LiNbO photonic quantum
circuits. These include the mode analyzer, a device that separates the even and
odd components of a state into two separate spatial paths; the mode rotator,
which rotates the state by an angle in mode space; and modal Pauli spin
operators that effect related operations. We also describe the design of a
deterministic, two-qubit, single-photon, CNOT gate, a key element in certain
sets of universal quantum logic gates. It is implemented as a Ti:LiNbO
photonic quantum circuit in which the polarization and mode number of a single
photon serve as the control and target qubits, respectively. It is shown that
the effects of dispersion in the CNOT circuit can be mitigated by augmenting it
with an additional path. The performance of all of these components are
confirmed by numerical simulations. The implementation of these transformations
relies on selective and controllable power coupling among single- and two-mode
waveguides, as well as the polarization sensitivity of the Pockels coefficients
in LiNbO
The ambiphilic nature of N-acyliminium ion-enamide tautomers. Novel annulation to enantiomerically pure polycyclic frameworks
Hydrophosphination of Bicyclo[1.1.0]butane-1-carbonitriles
Hydrophosphination
of bicyclo[1.1.0]Âbutyl nitriles with phosphine
boranes and phosphites provided novel cyclobutyl-P derivatives. The
reaction generally favors the <i>syn</i>-diastereomer, and
the nitrile can be reduced and converted to other functional groups,
thus enabling the preparation of bidentate ligands that access new
conformational space by virtue of their attachment to the torsionally
malleable but sterically restrictive cyclobutane scaffold. The enantioselective
hydrogenation of dehydrophenylalanine using a bidentate phosphine–phosphite
ligand illustrates the synthetic utility of the newly prepared scaffold
Atom-Economical Cross-Coupling of Internal and Terminal Alkynes to Access 1,3-Enynes
Selective carbon–carbon (C–C) bond formation in chemical synthesis generally requires pre-functionalized building blocks. However, the requisite pre-functionalization steps undermine the efficiency of multi-step synthetic sequences, which is particularly problematic in large-scale applications, such as in the commercial production of pharmaceuticals. Herein, we describe a selective and catalytic method for synthesizing 1,3-enynes without pre-functionalized building blocks. This method is facilitated by a tailored P,N-ligand that enables regioselective coupling and suppresses secondary E/Z-isomerization of the product. The transformation enables several classes of unactivated internal acceptor alkynes to be coupled with terminal donor alkynes to deliver 1,3-enynes in a highly regio- and stereoselective manner. The scope of compatible acceptor alkynes includes propargyl alcohols, (homo)propargyl amine derivatives, and (homo)propargyl carboxamides. The reaction is scalable and can operate effectively with 0.5 mol% catalyst loading. The products are versatile intermediates that can participate in various downstream transformations. We also present preliminary mechanistic experiments that are consistent with a redox-neutral Pd(II) catalytic cycle
Carbamoyl Anion Addition to Nitrones
The
addition of carbamoyl anions derived from <i>N</i>,<i>N</i>-disubstituted formamides and LDA to <i>N</i>-<i>tert</i>-butyl nitrones is described. The reaction
was demonstrated with a variety of formamides and nitrones and provided
a direct route to α-(<i>N</i>-hydroxy)Âamino amides.
The use of a <i>tert</i>-leucinol derived chiral auxiliary
on the nitrone provided products in good diastereoselectivity. Derivatization
of the products by <i>tert</i>-butyl deprotection or <i>N</i>-deoxygenation was demonstrated
Part 2: Designation and Justification of API Starting Materials: Current Practices across Member Companies of the IQ Consortium
The Reaction of Grignard Reagents with Bunte Salts: A Thiol-Free Synthesis of Sulfides
S-Alkyl,
S-aryl, and S-vinyl thiosulfate sodium salts (Bunte salts)
react with Grignard reagents to give sulfides in good yields. The
S-alkyl Bunte salts are prepared from odorless sodium thiosulfate
by an S<sub>N</sub>2 reaction with alkyl halides. A Cu-catalyzed coupling
of sodium thiosulfate with aryl and vinyl halides was developed to
access S-aryl and S-vinyl Bunte salts. The reaction is amenable to
a broad structural array of Bunte salts and Grignard reagents. Importantly,
this route to sulfides avoids the use of malodorous thiol starting
materials or byproducts
Part 2: Designation and Justification of API Starting Materials: Current Practices across Member Companies of the IQ Consortium
Designation and justification of
active pharmaceutical ingredient
starting material (API SM) is a standard part of the drug development
and commercialization process. However, knowledge of current practices
used within the industry varies, depending on the individual company
interpretation of regulatory guidelines. In 2011, the API and Analytical
Leadership Groups within the International Consortium for Innovation
and Quality in Pharmaceutical Development (IQ Consortium or IQ), established
a Working Group on API SMs to determine current practices within the
pharmaceutical industry on this topic. A survey composed of four key
areas, representing (1) drug substance (DS) attributes, (2) API SM
attributes, (3) control strategy, and (4) regulatory practices and
strategy, was developed and distributed to IQ member companies. Data
representing a total of 50 API SMs (used to prepare 24 late stage
clinical or marketed DSs) were obtained. This data was used to gain
a better understanding of approaches utilized by pharmaceutical companies
to define API SMs. The data gathered was anonymous, and the key information
obtained is summarized in this manuscript. While no single approach
to justifying API SMs emerged from the survey data, key trends were
evident that will provide valuable insight for the reader on this
important topic